May 3, 2016
BARCELONA — New data presented at the International Liver Congress showed patients with chronic hepatitis B virus infection who receive long-term treatment with nucleos(t)ide analogues did not have an increased risk for all cancers. However, a slight increase in the development of colorectal and cervical cancers was observed, suggesting routine screening for these types of cancers among these patients is necessary.
Grace Wong, MD, professor in the department of medicine and therapeutics at The Chinese University of Hong Kong, and colleagues evaluated the data of 44,494 patients with chronic HBV found in the Hospital Authority database between 2000 and 2012. Of these patients, 4,782 were treated with nucleos(t)ide analogues and 39,712 were not. The primary outcome was the incidence of malignancies other than hepatocellular carcinoma.